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The target  
While restenosis has been ascribed to an orchestrat- 
ed series of events including thrombosis, inflammation, 
smooth muscle cell migration and proliferation, matrix 
product ion,  and vascular emodeling, debate exists 
regarding the relative importance of these pathophysi- 
ologic mechanisms. M4 In one camp are those who 
propose that extraceUular matrix production and ceUu- 
lax migration and proliferation---or, neointimal hyper- 
plasia---cause luminal narrowing after vascular injury; 
and, in the other are those who emphasize the impor- 
tance of vascular remodeling, particularly after balloon 
angioplasty, as the chief determinant of late luminal 
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loss. To understand the pharmacology of stent-based 
adjuvant herapies, it is important o determine the 
time course over which the "target" of a given therapy 
is present, active, and susceptible to the treatment. 
Animal models of stent-induced arterial injury 
have revealed a characteristic time course of cellular 
migration and proliferation. While the pathophysio- 
logic mechanisms in the models are not identical to 
those of human coronary atherosclerosis, there are 
numerous imilarities that may be exploited. In the 
rabbit iliac artery, early recruitment of inflammatory 
cells, followed by migration of smooth muscle cells 
and proliferation within the media and neointima, is 
maximal 4 to 7 days after injury, and overall intimal 
size remains constant after 2 weeks. In porcine coro- 
nary models, vascular injury induces aggregation of 
mural thrombus within 24 hours; inflammatory cells 
adhere to and contribute to organization of throm- 
bus in 3 to 4 days. Smooth muscle cells proliferate, 
forming a thick neointima from 7 to 9 days after 
injury5 Macroscopic thrombus formation is based 
on the degree of injury--tearing of the internal elas- 
tic lamina--with exposure of the media serving as 
stimulus for platelet deposition, release of growth 
factors, and smooth muscle cell migration and pro- 
liferation. 7 Similar time course and pathophysiolog- 
ic mechanisms have been described in an atheroscle- 
rotic rabbit double-injury model. 
Rcgardlcss of the major contributor to the 
process of restenosis, multiple cellular and chemical 
targets exist for inhibition through local drug deliv- 
ery. Growth factors and cytokines regulate the 
migration and proliferation of the cellular compo- 
nents of restenosis. Smooth muscle cell prolifera- 
tion can be influenced and regulated by PDGF, 
bFGF, HB-EGF, IGF-1, IL-1, TNF-alpha, and 
TGF-beta. Smooth musclc cell chemotaxis can be 
induced by PDGF or IGF-1. Monocyte chemotaxis 
is influenced by CSFs, MCP-1, oxLDL, and TGF- 
beta. bFGF also serves as an endothelial mitogen 
and chemoattractant and a smooth muscle cell 
mitogen. The immune response to injury may 
involve IL-I, TNF-alpha, IFN-gamma, IL-2, and 
CSFs. By identifying the subcellular targets and the 
time course of their activity, we may better antici- 
pate methods through which stent-based local drug 
delivery can inhibit these mechanisms and reduce 
restenosis. 
The platform 
While many catheter-based delivery systems dis- 
pense medication at one given point in time, other 
strategies have been developed to provide a reser- 
voir of sustained rug release. The advantage of an 
ideal stent-based delivery device might be in its abil- 
ity to provide drug to a particular site at a particu- 
lar time, thereby conferring target specificity. 
Several biodegradable and nonbiodegradable 
polymer stent coatings have been found to provide 
prolonged drug delivery with no significant local 
toxicity. Van der Giessen et a115 examined the effect 
of coating tantalum stents with such polymers to 
assess the prospect of devising a reservoir for sus- 
tained endoluminal drug delivery. Regions of 
porcine coronary arteries exposed to polymer-coat- 
ed stents exhibited significantly greater inflammat- 
ory and proliferative cellular response compared 
with regions exposed to bare tantalum stent. 
Similarly, self-expanding polymeric stents created 
from polytethylene t rephthalate engendered pro- 
found neointimal hyperplasia nd a chronic inflam- 
matory response in porcine coronary arteries. 16 
Such "foreign body response" and acute inflamma- 
tion might be attributed to direct toxicity of the 
polymer, disruption of the dynamic physiology of 
the luminal surface with appro~mated polymer, or 
humoral incompatibility.IS, 16 
Using a heat-activated removable temporary 
stent, Lambert et all7 developed a platform that per- 
mitted sustained rug release to the arterial uminal 
surface from a removable reservoir. Forskolin was 
delivered to the vessel wall from a polyurethane stent 
coating at concentrations 460-fold that recovered 
systemically. Drug delivered in this fashion exerted a
biological effect, promoting 92% increased blood 
flow and 60% decreased vascular esistance because 
of its vasodilatory effects. Following crush injury of 
the vessel receiving the stent, time to thrombosis 
was 12-fold longer than in comparable arteries with 
uncoated stents. In a similar manner, tantalum stents 
coated with fibrin and soaked in heparin reduced 
subacute thrombosis in pig coronary arteries. While 
control stents coated with polyurethane created sub- 
acute thrombosis and death in 50% of animals and 
foreign-body inflammatory total occlusion in the 
other 50%, the heparin-loaded stents provoked sub- 
acute thrombosis in less than 9%. 18 
Stents with covalently bound heparin were also 
found to reduce the rate of thrombosis. Thrombosis 
was observed in porcine coronary arteries implanted 
with heparin-bound stents, compared with 37% 
thrombosis in vessels stented without bound 
heparin. 19 Similar reduction in fibrinogen and 
platelet adhesion was noted in response to heparin- 
coated stents by de Scheerder et a12°; but compared 
with uncoated stents, the heparin coating produced 
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no significant difference in intrastent luminal diame- 
ter at 6-week follow-up. In stented arteries, the 
chronic inflammatory stimulus and deep vessel wall 
injury of stent wire might outweigh the influence of 
thrombosis on determining late luminal oss. Some 
benefit may have been observed when these stents 
were used clinically. In the Benestent-II pilot study, 
heparin-coated stents appear to have reduced the 
requirement for systemic anticoagulation and its 
attendant complications, yielding a lower bleed rate 
(0%-7.9%), shorter hospital stays (3.1-7 days), and 
perhaps a lower rate of restenosis (13%) compared 
with Benestent-I. 21
Platform/target synchrony 
Catheter-based delivery systems permit site-spe- 
cific delivery of drugs, but for agents to exert the 
desired clinical effect, they must be delivered at the 
appropriate time to ensure interaction with the tar- 
get. In injured and stented rabbit iliac arteries, stent 
thrombosis occurs within 24 hours of injury, where- 
as smooth muscle cell proliferation is maximal at 7 
days after injury and may continue up to 28 days 
thereafter. Without heparin therapy, thrombosis 
occurs in 42% of stented arteries; with continuous 
intravenous or polymer matrix sustained release of 
heparin, no thrombosis was observed. With heparin- 
coated stents, thrombosis was seen in 8%. Since 
thrombosis i a relatively early event, it is significant- 
ly attenuated even with "burst" delivery of heparin 
from a heparin-coated stent. Smooth muscle cell 
proliferation, a sustained physiologic process in 
response to the chronic inflammatory stimulus of 
the stent in the injured vessel, cannot be controlled 
by stent-based "burst" delivery of heparin. Sustained 
perivascular release of heparin from polymer matri- 
ces reduced intimal area by 29% versus controls 
when restricted to 3 days after injury and by 54% 
when release was maintained for the duration of the 
experiment. It may well be that chronic delivery of 
the medication is necessary to inhibit smooth mus- 
cle cell proliferation i response to the chronic njury 
engendered by the stent. 9
Monocyte adhesion is believed to be an earlier 
mediator in the process that governs neointimal 
hyperplasia after vascular injury. The time course of 
administration of heparin determines the effect on 
inhibition of monocyte adhesion in injured and 
stented rabbit iliac arteries. Heparin delivered by 
continuous intravenous or by EVAc perivascular 
matrix for 14 days after stenting inhibited monocyte 
adhesion threefold compared with controls. 
Delivery of heparin by either mechanism for 3 days 
was less effective at inhibiting monocyte adhesion. 
The relatively brief administration f heparin from a 
heparin-loaded stent only minimally reduced mono- 
cyte adhesion. Sustained elivery ofheparin was need- 
ed to parallel the time course of monocyte adhesion: 
monocytes are maximally adherent to he lttminal sur- 
face at 3 days after injury; at 7 days, there was a 48.5% 
reduction of monocytes adherent to he lumen with a 
10-fold increase in number located within the vessel 
wall, coincident with peak cell proliferation; and at 14 
days, only 10% of the original number of monocytes 
were evident at the lumen. The infiltrating monocyte 
density was reduced by 43%. 22 
Recent efforts have focused on novel additions 
to stented vessels, including radiation-emitting iso- 
topes, cell cycle regulatory agents uch as rapamycin, 
and the antineoplastic drug palcitaxel. 
Conclusion 
Restenosis  the net result of a complex, coordinat- 
ed sequence of events. While animal models may 
not precisely mirror the physiology of human 
atherosclerotic disease, they may offer a framework in 
which to study many of the constituent processes. 
Techniques of local drug delivery serve as valuable tools 
both for research of the mechanisms of restenosis and 
in potential strategies for clinical benefit. The physio- 
logic impact may be maximized, with minimal systemic 
toxicity, by developing modalities to bring medications 
together with the intended target in a manner that is 
specific both to the site and the timing of the target's 
availability. Further study of techniques of local delivery 
may advance our knowledge in the mechanisms of 
restenosis and the strategies with which to combat it. 
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CONTROLLED RELEASE STENTS FOR 
RESTENOSIS 
Robert J. Levy, MD 
The Children Hospital ofPhiladelphia 
Philadelphia, Pa 
Expandable stents used for the relief o f  arterial 
obstruction have led to major progress in interven- 
tional cardiology, especially the treatment o f  coronary 
artery disease. Stents mechanically relieve obstructive 
vascular disease, thereby providing at least short-term 
efficacy. However, a number o f  concerns exist con- 
cerning stents, especially with respect o the continu- 
ing presence of  underlying vascular disease in stented 
arteries, and the recognized existence of  stent-related 
pathology in the form of  in-stent restenosis. 
One solution to this problem has been to consid- 
er the prospect of  stent mediated rug delivery. This 
approach is based on the hypothesis that the frame- 
work o f  a vascular stent can be used as a support for 
a polymer drug delivery system, which could provide 
a therapeutic agent to the arterial wall underlying the 
expanded stent, There are a number o f  challenges to 
this approach. First o f  all, drug delivery preparations 
must be in and of  themselves expandable, to conform 
to the changing dimensions o f  the stent on expan- 
sion. Furthermore, the delivery capacity o f  the stent, 
due to its thin framework, is limited. Thus, it is o f  
importance to identify drugs with a very high poten- 
cy to mass ratio to optimize drug effects. 
Furthermore, the duration o f  drug delivery may also 
be a problem in terms of  the finite capacity o f  the 
stent to contain a relevant herapeutic agent. 
All o f  the above considerations are based on the 
premise that the optimal therapeutic approach is at 
some point understood. At present, this is not the 
case. Nevertheless, ome general principles related to 
stent-mediated drug delivery have been formulated 
and have been investigated in experimental studies. 
Since a major component  of in-stent restenosis i  
smooth muscle cell proliferation, several successful 
therapeutic studies have been carried out using phar- 
maceutical agents designed to inhibit smooth mus- 
cle cell proliferation. The most promising drug used 
in this approach as been the anticancer agent Taxol. 
Taxol is highly potent  and also highly toxic. 
Nevertheless, in experimental studies the inhibition 
o f  smooth muscle cell proliferation in stented arter- 
ies receiving a Taxol delivery stent is significant and 
has led to device technology development)  
Another promising approach, from the point o f  
view of  potency and long-acting therapeutic effects, 
is the gene delivery stent. Two model systems have 
been considered thus far. In  one approach, an 
